ImmunityBio Revenue Climbs 53% as Quarterly Loss Widens

ImmunityBio said Monday its third-quarter net product revenue rose 53% year over year, while its net loss widened and its ANKTIVA-plus-BCG regimen met the primary endpoint in a bladder cancer trial.

Net product revenue reached $48.7 million in the quarter. For the first nine months of 2026, it totaled $143.6 million, up 92% from a year earlier. Cash, cash equivalents and marketable securities stood at $334.3 million on Sept. 30.

Net loss attributable to common stockholders was $184.6 million, compared with $67.3 million in the year-earlier quarter. ImmunityBio attributed much of the increase to noncash fair-value changes in a related-party convertible note and warrant liabilities.

Research and development expense rose to $71.5 million from $51.2 million. Selling, general and administrative expense increased to $54 million from $36.3 million.

For Cohort A, ImmunityBio said ANKTIVA plus BCG met the primary endpoint in QUILT-2.005, a randomized trial of 370 patients with BCG-naive, high-grade non-muscle-invasive bladder cancer. The company said the combination showed a statistically significant efficacy improvement over BCG alone among patients with carcinoma in situ, with or without papillary tumors.

Side effects were consistent with those seen with BCG alone. ImmunityBio said no treatment-related deaths occurred.

The company plans to submit a supplemental biologics license application to the U.S. Food and Drug Administration before the end of 2026 for use in BCG-naive patients.